Molbio Diagnostics rises 2.5% after Jefferies initiates with buy and PT 1,600 rupees

Molbio Diagnostics shares rose 2.5% to 1,287 rupees after Jefferies initiated coverage with a buy rating and a 1,600-rupee price target. Jefferies cited Molbio’s Truenat platform, saying it is lighter, faster and less infrastructure-dependent than Cepheid’s GeneXpert.